JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation

Daijiro Harada, Nagio Takigawa, Nobuaki Ochi, Takashi Ninomiya, Masayuki Yasugi, Toshio Kubo, Hiromasa Takeda, Eiki Ichihara, Kadoaki Oohashi, Saburo Takata, Mitsune Tanimoto, Katsuyuki Kiura

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib and erlotinib, are effective for non-small cell lung cancer with activating EGFR mutations. However, even in patients with an initial dramatic response to such a drug, acquired resistance develops after 6-12 months. A secondary mutation of T790M in EGFR and amplification of the MET gene account for this resistance; however, the mechanism(s) of approximately 30% of acquired resistance cases remain unknown. We established an erlotinib-resistant lung cancer cell line named PC-9/ER3 that harbors an EGFR mutation after continuously exposing PC-9 cells to erlotinib. PC-9/ER3 cells were 136-fold more resistant to erlotinib than the parental cells. Although the PC-9/ER3 cells did not carry the T790M mutation or MET amplification and had similar levels of phosphorylated (p) STAT3, pJAK2 increased in the resistant cells. It was found in the present study that 3-12 h of exposure to erlotinib in both cell lines did not affect pJAK2 expression, but did result in increased pSTAT3 expression. pAkt in PC-9/ER3 cells was less suppressed than in PC-9 cells, although pEGFR and pMAPK were markedly suppressed in both cell lines. The combined treatment of erlotinib plus a JAK2 inhibitor (JSI-124) suppressed pAkt in PC-9/ER3 cells. Similarly, the combination of erlotinib plus JSI-124 or siRNA against JAK2 restored sensitivity to erlotinib in PC-9/ER3 cells. The combination of erlotinib plus JSI-124 was also effective for reducing PC-9/ER3 tumors in a murine xenograft model. Our results suggest that the activation of JAK2 partially accounts for acquired erlotinib resistance.

Original languageEnglish
Pages (from-to)1795-1802
Number of pages8
JournalCancer Science
Volume103
Issue number10
DOIs
Publication statusPublished - Oct 2012

Fingerprint

Epidermal Growth Factor Receptor
Lung Neoplasms
Mutation
Cell Line
Erlotinib Hydrochloride
Gene Amplification
Drug Resistance
Heterografts
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Small Interfering RNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation. / Harada, Daijiro; Takigawa, Nagio; Ochi, Nobuaki; Ninomiya, Takashi; Yasugi, Masayuki; Kubo, Toshio; Takeda, Hiromasa; Ichihara, Eiki; Oohashi, Kadoaki; Takata, Saburo; Tanimoto, Mitsune; Kiura, Katsuyuki.

In: Cancer Science, Vol. 103, No. 10, 10.2012, p. 1795-1802.

Research output: Contribution to journalArticle

Harada, Daijiro ; Takigawa, Nagio ; Ochi, Nobuaki ; Ninomiya, Takashi ; Yasugi, Masayuki ; Kubo, Toshio ; Takeda, Hiromasa ; Ichihara, Eiki ; Oohashi, Kadoaki ; Takata, Saburo ; Tanimoto, Mitsune ; Kiura, Katsuyuki. / JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation. In: Cancer Science. 2012 ; Vol. 103, No. 10. pp. 1795-1802.
@article{fa6d2c9be2e645cfbbe146d9ba261939,
title = "JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation",
abstract = "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib and erlotinib, are effective for non-small cell lung cancer with activating EGFR mutations. However, even in patients with an initial dramatic response to such a drug, acquired resistance develops after 6-12 months. A secondary mutation of T790M in EGFR and amplification of the MET gene account for this resistance; however, the mechanism(s) of approximately 30{\%} of acquired resistance cases remain unknown. We established an erlotinib-resistant lung cancer cell line named PC-9/ER3 that harbors an EGFR mutation after continuously exposing PC-9 cells to erlotinib. PC-9/ER3 cells were 136-fold more resistant to erlotinib than the parental cells. Although the PC-9/ER3 cells did not carry the T790M mutation or MET amplification and had similar levels of phosphorylated (p) STAT3, pJAK2 increased in the resistant cells. It was found in the present study that 3-12 h of exposure to erlotinib in both cell lines did not affect pJAK2 expression, but did result in increased pSTAT3 expression. pAkt in PC-9/ER3 cells was less suppressed than in PC-9 cells, although pEGFR and pMAPK were markedly suppressed in both cell lines. The combined treatment of erlotinib plus a JAK2 inhibitor (JSI-124) suppressed pAkt in PC-9/ER3 cells. Similarly, the combination of erlotinib plus JSI-124 or siRNA against JAK2 restored sensitivity to erlotinib in PC-9/ER3 cells. The combination of erlotinib plus JSI-124 was also effective for reducing PC-9/ER3 tumors in a murine xenograft model. Our results suggest that the activation of JAK2 partially accounts for acquired erlotinib resistance.",
author = "Daijiro Harada and Nagio Takigawa and Nobuaki Ochi and Takashi Ninomiya and Masayuki Yasugi and Toshio Kubo and Hiromasa Takeda and Eiki Ichihara and Kadoaki Oohashi and Saburo Takata and Mitsune Tanimoto and Katsuyuki Kiura",
year = "2012",
month = "10",
doi = "10.1111/j.1349-7006.2012.02363.x",
language = "English",
volume = "103",
pages = "1795--1802",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation

AU - Harada, Daijiro

AU - Takigawa, Nagio

AU - Ochi, Nobuaki

AU - Ninomiya, Takashi

AU - Yasugi, Masayuki

AU - Kubo, Toshio

AU - Takeda, Hiromasa

AU - Ichihara, Eiki

AU - Oohashi, Kadoaki

AU - Takata, Saburo

AU - Tanimoto, Mitsune

AU - Kiura, Katsuyuki

PY - 2012/10

Y1 - 2012/10

N2 - Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib and erlotinib, are effective for non-small cell lung cancer with activating EGFR mutations. However, even in patients with an initial dramatic response to such a drug, acquired resistance develops after 6-12 months. A secondary mutation of T790M in EGFR and amplification of the MET gene account for this resistance; however, the mechanism(s) of approximately 30% of acquired resistance cases remain unknown. We established an erlotinib-resistant lung cancer cell line named PC-9/ER3 that harbors an EGFR mutation after continuously exposing PC-9 cells to erlotinib. PC-9/ER3 cells were 136-fold more resistant to erlotinib than the parental cells. Although the PC-9/ER3 cells did not carry the T790M mutation or MET amplification and had similar levels of phosphorylated (p) STAT3, pJAK2 increased in the resistant cells. It was found in the present study that 3-12 h of exposure to erlotinib in both cell lines did not affect pJAK2 expression, but did result in increased pSTAT3 expression. pAkt in PC-9/ER3 cells was less suppressed than in PC-9 cells, although pEGFR and pMAPK were markedly suppressed in both cell lines. The combined treatment of erlotinib plus a JAK2 inhibitor (JSI-124) suppressed pAkt in PC-9/ER3 cells. Similarly, the combination of erlotinib plus JSI-124 or siRNA against JAK2 restored sensitivity to erlotinib in PC-9/ER3 cells. The combination of erlotinib plus JSI-124 was also effective for reducing PC-9/ER3 tumors in a murine xenograft model. Our results suggest that the activation of JAK2 partially accounts for acquired erlotinib resistance.

AB - Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib and erlotinib, are effective for non-small cell lung cancer with activating EGFR mutations. However, even in patients with an initial dramatic response to such a drug, acquired resistance develops after 6-12 months. A secondary mutation of T790M in EGFR and amplification of the MET gene account for this resistance; however, the mechanism(s) of approximately 30% of acquired resistance cases remain unknown. We established an erlotinib-resistant lung cancer cell line named PC-9/ER3 that harbors an EGFR mutation after continuously exposing PC-9 cells to erlotinib. PC-9/ER3 cells were 136-fold more resistant to erlotinib than the parental cells. Although the PC-9/ER3 cells did not carry the T790M mutation or MET amplification and had similar levels of phosphorylated (p) STAT3, pJAK2 increased in the resistant cells. It was found in the present study that 3-12 h of exposure to erlotinib in both cell lines did not affect pJAK2 expression, but did result in increased pSTAT3 expression. pAkt in PC-9/ER3 cells was less suppressed than in PC-9 cells, although pEGFR and pMAPK were markedly suppressed in both cell lines. The combined treatment of erlotinib plus a JAK2 inhibitor (JSI-124) suppressed pAkt in PC-9/ER3 cells. Similarly, the combination of erlotinib plus JSI-124 or siRNA against JAK2 restored sensitivity to erlotinib in PC-9/ER3 cells. The combination of erlotinib plus JSI-124 was also effective for reducing PC-9/ER3 tumors in a murine xenograft model. Our results suggest that the activation of JAK2 partially accounts for acquired erlotinib resistance.

UR - http://www.scopus.com/inward/record.url?scp=84867229376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867229376&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2012.02363.x

DO - 10.1111/j.1349-7006.2012.02363.x

M3 - Article

C2 - 22712764

AN - SCOPUS:84867229376

VL - 103

SP - 1795

EP - 1802

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 10

ER -